Breaking News: AnPac Bio Announces Preliminary Results From Prospective Trials Indicating Early-Stage Cancer Screening Effectiveness | Financial Buzz

Breaking News: AnPac Bio Announces Preliminary Results From Prospective Trials Indicating Early-Stage Cancer Screening Effectiveness

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today preliminary results from two prospective studies demonstrated that AnPac Bio’s Cancer Differentiation Analysis (CDA) based tests have the ability to assess the risks of cancer occurrence. 

In a study of follow-up phone consultations commenced in 2017, over 13,000 individuals (including individuals tested with high risk, medium risk and low risk CDA scores) had provided the company with substantive feedback regarding their health conditions and disease development as of July 31, 2020, and among them, there had been diagnosed over 190 cancer cases, over 900 pre-cancer cases, and 700 disease cases, with higher predictive values being statistically significantly higher from individuals with higher CDA scores. In another prospective study that began last year with close to 2,000 individuals of 65 years old or above, 10 cancer cases have been confirmed. The above results demonstrated that CDA technology is capable of assessing pre-cancer and early stage cancer risks. 

AnPac Bio’s CEO, Dr. Chris Yu, commented, “while there are a number of cancer screening technologies aimed at detecting cancer early, only a limited number of them have proven the ability to do so, with many of them still in the R&D phase. AnPac Bio’s CDA technology has been demonstrated, in both retrospective and prospective studies, to be able to detect pre-cancer disease and early stage cancer signals with statistical significance. We are proud to be saving lives.”

Dr. Chris Yu continued, “Cancer screening markets in both US and China are significant and growing. The current global cancer diagnostics market size is $144 Billion and expected to grow up to $249 Billion by 2026. We believe that AnPac Bio is well positioned to capture these markets with our innovative technology, significant patent portfolio, one of the world’s largest clinical sample size among companies offering next-generation early cancer screening and detection technologies, and extensive experience in cancer screening and detection.”

About AnPac Bio

AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 128 issued patents as of June 30, 2020. With two certified clinical laboratories in China and one CLIA and CAP accredited clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests. According to Frost & Sullivan, AnPac Bio ranked third worldwide and first in China among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection, based on approximately 41,700 clinical samples as at May 2020. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity.

For more information, please visit:

Sponsored Content Release. Click for Full Disclosure

  • Sponsored Content Release, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. has not been compensated directly by any of the companies mentioned here in this editorial unless mentioned otherwise. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For AnPac Bio-Medical Science Co., Ltd. video production, filming editing, news reporting, financial and corporate news dissemination, has signed a two month agreement with the Company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. has agreed to seventy thousand restricted shares, will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: